Literature DB >> 19825522

Circulating levels of TNF-alpha and its soluble receptors in the plasma of patients with epithelial ovarian cancer.

Bozena Dobrzycka1, Slawomir J Terlikowski, Oksana Kowalczuk, Maciej Kinalski.   

Abstract

The significance of circulating levels of TNF-alpha and its soluble receptors (sTNF-Rs) in the plasma of patients with epithelial ovarian cancer (EOC) has not been fully elucidated. The present study was to investigate the relationship of pretreatment plasma levels of TNF-alpha, sTNFR-1 and sTNFR-2 with outcome in 126 patients with EOC. Concentrations of TNF-alpha and sTNF-Rs were determined by enzyme-linked immunosorbent assay (ELISA). Median TNF-alpha and sTNF-Rs levels were significantly higher in EOC patients than in healthy controls. High plasma levels of TNF-alpha and sTNF-Rs were correlated with tumor stage and with reduced mean survival time (MST). The results of the present study suggested that preoperative plasma TNF-alpha and sTNF-Rs levels in EOC patients correlated with the highest risk of cancer progression. Thus, the clinical value of an activated TNF system in EOC needs to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19825522     DOI: 10.1684/ecn.2009.0161

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  16 in total

1.  Plasma immune analytes in patients with epithelial ovarian cancer.

Authors:  Matthew S Block; Matthew J Maurer; Krista Goergen; Kimberly R Kalli; Courtney L Erskine; Marshall D Behrens; Ann L Oberg; Keith L Knutson
Journal:  Cytokine       Date:  2015-03-03       Impact factor: 3.861

2.  TNF-R2 in tumor microenvironment as prognostic factor in epithelial ovarian cancer.

Authors:  Rosekeila Simões Nomelini; Luciano Eliziário Borges Júnior; Cid Almeida de Lima; Ana Flávia Carrijo Chiovato; Douglas Côbo Micheli; Beatriz Martins Tavares-Murta; Eddie Fernando Candido Murta
Journal:  Clin Exp Med       Date:  2018-05-25       Impact factor: 3.984

3.  A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer.

Authors:  Elizabeth M Poole; I-Min Lee; Paul M Ridker; Julie E Buring; Susan E Hankinson; Shelley S Tworoger
Journal:  Am J Epidemiol       Date:  2013-08-21       Impact factor: 4.897

4.  Characteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells.

Authors:  Deok-Soo Son; Syeda M Kabir; Yuanlin Dong; Eunsook Lee; Samuel E Adunyah
Journal:  J Inflamm (Lond)       Date:  2013-06-25       Impact factor: 4.981

5.  Immunohistochemical staining of tumor necrosis factor-α and interleukin-10 in benign and malignant ovarian neoplasms.

Authors:  Millena Prata Jammal; Allison Araújo DA Silva; Agrimaldo Martins Filho; Eliângela DE Castro Côbo; Sheila Jorge Adad; Eddie Fernando Candido Murta; Rosekeila Simões Nomelini
Journal:  Oncol Lett       Date:  2014-12-08       Impact factor: 2.967

6.  NF-κB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression.

Authors:  Rosa Mistica C Ignacio; Syeda M Kabir; Eun-Sook Lee; Samuel E Adunyah; Deok-Soo Son
Journal:  PLoS One       Date:  2016-10-10       Impact factor: 3.240

7.  Higher serum levels of tumour necrosis factor and its soluble receptors are associated with ovarian tumours.

Authors:  Aleksandra Mielczarek-Palacz; Zdzisława Kondera-Anasz; Justyna Sikora
Journal:  Arch Med Sci       Date:  2012-10-30       Impact factor: 3.318

8.  CXCR2-driven ovarian cancer progression involves upregulation of proinflammatory chemokines by potentiating NF-κB activation via EGFR-transactivated Akt signaling.

Authors:  Yuan-Lin Dong; Syeda M Kabir; Eun-Sook Lee; Deok-Soo Son
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

9.  Cytokines and Prognostic Factors in Epithelial Ovarian Cancer.

Authors:  Millena Prata Jammal; Agrimaldo Martins-Filho; Thales Parenti Silveira; Eddie Fernando Candido Murta; Rosekeila Simões Nomelini
Journal:  Clin Med Insights Oncol       Date:  2016-08-02

10.  Soluble tumour necrosis factor receptor type II and survival in colorectal cancer.

Authors:  Ana Babic; Sonali M Shah; Mingyang Song; Kana Wu; Jeffrey A Meyerhardt; Shuji Ogino; Chen Yuan; Edward L Giovannucci; Andrew T Chan; Meir J Stampfer; Charles S Fuchs; Kimmie Ng
Journal:  Br J Cancer       Date:  2016-03-31       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.